Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy

Ítems similars

• Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment.
  per: Palittiya Sintusek, et al.
  Publicat: (2016-01-01)
• Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment
  per: Sintusek, Palittiya, et al.
  Publicat: (2016)
• The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
  per: Haiyan Zhou, et al.
  Publicat: (2020-10-01)
• The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
  per: Zhou, Haiyan, et al.
  Publicat: (2020)
• Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
  per: Catapano, Francesco, et al.
  Publicat: (2016)